KLA Corp. vs State Street SPDR S&P Biotech ETF — how do they compare? KLA Corp. trades at $208.41 (market cap $261.92B), while State Street SPDR S&P Biotech ETF trades at $159.35. The key difference: KLA Corp. pays a 0.46% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, KLA Corp. nearer its low. Which is the better fit depends on your goals.
| KLAC | XBI | |
|---|---|---|
Market Cap | $261.92B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $301.71 | $164.28 |
52-Week Low | $84.39 | $86.92 |
Enterprise Value | $263.17B | — |
Dividend Yield | 0.46% | — |
Signals from Pluang's Aura AI — not financial advice
KLA Corporation (KLAC) trades at $208.27, up 8.06% on the day, reflecting strong momentum amid the AI-driven semiconductor equipment rally. The stock exhibits bullish technical signals with recent earnings beats and robust profitability, including a 35.57% net income margin. Recent corporate actions include a 1:10 stock split and dividend declarations, while analyst consensus leans heavily bullish with a $246.93 price target.
Outlook remains positive given KLAC's exposure to advanced packaging growth and AI chip demand, though elevated valuation ratios (P/E of 54.77) and technical overbought conditions near resistance at $209 pose near-term risks. Long-term investors may find value in its fundamental strength, but volatility from sector cyclicality warrants caution.
XBI, the SPDR S&P Biotech ETF, trades at $159.39, up 0.86% on the day, with a bullish technical signal driven by moving averages. The fund holds 155 biotech stocks, benefiting from strong sector momentum, including a 17% gain in June 2026 (ETF Trends, 2026-07-01). Recent news highlights institutional buying and positive drug trial outcomes fueling the rally.
Outlook: Biotech sector tailwinds from M&A, AI drug discovery, and clinical successes support further upside, but high volatility and policy risks persist. Investors gain diversified exposure to small- and mid-cap biotech innovation, though the 0.35% expense ratio and lack of dividend yield may deter income-focused buyers.
Trailing returns across standard periods
Latest headlines on both assets
KLA designs and manufactures yield-management and process-monitoring diagnostic and control systems for the semiconductor manufacturing industry. The systems are used to analyze the manufacturing process at various steps in a semiconductor's development. The firm's laser-scanning products are used for wafer qualification, process monitoring, and equipment monitoring. KLA also provides inspection tools and systems for optical metrology and e-beam metrology.
Read more on KLAC →XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →